Get the Stockscreener App
76.69
0.77%
0.585
After Hours:
76.53
-0.155
-0.20%
Ani Pharmaceuticals Inc stock is traded at $76.69, with a volume of 624.51K.
It is up +0.77% in the last 24 hours and down -5.64% over the past month.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
See More
Previous Close:
$76.10
Open:
$76.07
24h Volume:
624.51K
Relative Volume:
1.43
Market Cap:
$1.72B
Revenue:
$747.40M
Net Income/Loss:
$-12.60M
P/E Ratio:
-99.76
EPS:
-0.7687
Net Cash Flow:
$105.18M
1W Performance:
+0.50%
1M Performance:
-5.64%
6M Performance:
-20.12%
1Y Performance:
+29.69%
1-Day Range:
$74.80
$77.20
1-Week Range:
$72.43
$78.00
52-Week Range:
$56.71
$99.50
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Name
Ani Pharmaceuticals Inc
Sector
Phone
(218) 634-3500
Address
210 MAIN STREET WEST, BAUDETTE, MN
Compare ANIP vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
76.69 | 1.71B | 747.40M | -12.60M | 105.18M | -0.7687 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.98 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.48 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.88 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Initiated | H.C. Wainwright | Buy |
| Mar-14-25 | Initiated | Jefferies | Buy |
| Mar-12-25 | Initiated | JP Morgan | Overweight |
| Dec-11-24 | Initiated | Leerink Partners | Outperform |
| Oct-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-15-24 | Initiated | CapitalOne | Overweight |
| Aug-22-23 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Sep-07-22 | Initiated | H.C. Wainwright | Buy |
| Nov-02-21 | Initiated | Truist | Buy |
| May-07-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| May-10-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-16-17 | Reiterated | Canaccord Genuity | Buy |
| Jul-31-17 | Initiated | Canaccord Genuity | Buy |
| Feb-22-17 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-23-16 | Initiated | Raymond James | Strong Buy |
| May-24-16 | Downgrade | Standpoint Research | Buy → Hold |
| Nov-13-15 | Initiated | Standpoint Research | Buy |
| Sep-28-15 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-05-15 | Reiterated | Oppenheimer | Outperform |
| Aug-04-15 | Reiterated | ROTH Capital | Neutral |
| Jul-31-15 | Reiterated | Oppenheimer | Outperform |
| Jul-15-15 | Reiterated | ROTH Capital | Neutral |
| Jun-23-15 | Reiterated | Oppenheimer | Outperform |
| May-18-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Reiterated | Oppenheimer | Outperform |
| Apr-10-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-26-15 | Reiterated | ROTH Capital | Buy |
| Feb-18-15 | Reiterated | Oppenheimer | Outperform |
View All
Ani Pharmaceuticals Inc Stock (ANIP) Latest News
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M - Finviz
Director at ANI Pharmaceuticals (ANIP) sells 6,000 shares - Stock Titan
SVP & CFO At ANI Pharmaceuticals Buys $1.72M of Stock - Benzinga
833K Reasons To Be Bullish On ANI Pharmaceuticals Stock - Benzinga
SVP Of ANI Pharmaceuticals Makes $1.00M Buy - Benzinga
SVP Of ANI Pharmaceuticals Purchased $464K In Stock - Benzinga
ANI Pharmaceuticals (ANIP) Stock Analysis: A Compelling 47% Upside Potential Awaits Investors - DirectorsTalk Interviews
ANI Pharmaceuticals Targets $1B+ Sales in 2026, Pivots to Rare Disease Growth at Raymond James Conf. - Yahoo Finance
ANI Pharmaceuticals at Raymond James Conference: Rare Disease Focus By Investing.com - Investing.com Canada
ANI Pharmaceuticals Highlights Updated Non-GAAP Metrics to Investors - TipRanks
ANI Pharmaceuticals projects >$1B revenue in 2026, guides $275–$290M adjusted EBITDA - TradingView
ANI Pharmaceuticals : Corporate Presentation March 2026 - marketscreener.com
ANI Pharmaceuticals (NASDAQ: ANIP) guides to over $1B in 2026 revenue - Stock Titan
ANI Pharmaceuticals (NASDAQ: ANIP) exec granted 11,116 shares - Stock Titan
ANI Pharmaceuticals (ANIP) SVP receives stock award, withholds shares for taxes - Stock Titan
ANI Pharmaceuticals (ANIP) exec logs stock award and tax share disposal - Stock Titan
ANI Pharmaceuticals (ANIP) CEO logs restricted stock grant and tax-withholding share disposition - Stock Titan
ANI Pharmaceuticals (ANIP) SVP logs stock grant and tax withholding in Form 4 - Stock Titan
ANI Pharmaceuticals (ANIP) SVP reports stock award, tax withholding and LLC-held shares - Stock Titan
ANI Pharmaceuticals (ANIP) HR chief reports stock award and tax withholding - Stock Titan
Restricted stock grant for ANI Pharmaceuticals (ANIP) general counsel - Stock Titan
ANI Pharmaceuticals (ANIP) CFO awarded restricted stock and has shares withheld for taxes - Stock Titan
LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata - Finviz
ANI Pharmaceuticals Q4 2025: Strong Growth, But Execution Risks Emerge (NASDAQ:ANIP) - Seeking Alpha
William Blair Investment Management LLC Sells 141,856 Shares of ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Quantbot Technologies LP Has $4.20 Million Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Does Record 2025 Profitability and Reaffirmed 2026 Outlook Change The Bull Case For ANI Pharmaceuticals (ANIP)? - simplywall.st
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2025 Earnings Call Transcript - Insider Monkey
ANI Pharmaceuticals (NASDAQ:ANIP) Beats Expectations in Strong Q4 CY2025, Stock Jumps 12.4% - The Globe and Mail
Clover Health, Alignment Healthcare, Solventum, ANI Pharmaceuticals, and Guardant Health Shares Plummet, What You Need To Know - The Globe and Mail
Decoding ANI Pharmaceuticals Inc (ANIP): A Strategic SWOT Insigh - GuruFocus
ANI Pharma Q4 2025 slides: rare disease shift drives 44% revenue growth - Investing.com Australia
ALIM Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Earnings call transcript: ANI Pharmaceuticals Q4 2025 earnings beat expectations - Investing.com Nigeria
ANI Pharmaceuticals Inc (ANIP) Q4 2025 Earnings Call Highlights: Record Revenue and Strong ... By GuruFocus - Investing.com Canada
ANI Pharmaceuticals Reports Strong Q4 Earnings Growth - Intellectia AI
ANI Pharmaceuticals Reports Q4 Net Income Growth - Intellectia AI
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus - Finviz
ANI Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ANIP) 2026-02-27 - Seeking Alpha
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line - Finviz
ANI Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
ANI Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
ANI Pharma (ANIP) Q4 2025 Earnings Call Transcript - The Globe and Mail
ANI Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
ANI Pharmaceuticals Turns Profit, Rare Disease Sales Surge 50% - Benzinga
ANI Pharmaceuticals Posts Record 2025 Results on Rare Disease Growth - TipRanks
ANI Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ANI Pharmaceuticals (ANIP) Stock: Revenue Jumps 44% as Rare Disease Pipeline Transforms Outlook - CoinCentral
Ani Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Full Year 2026 - marketscreener.com
ANI Pharmaceuticals (ANIP) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance
ANI PHARMACEUTICALS ($ANIP) Releases Q4 2025 Earnings - Quiver Quantitative
Ani Pharmaceuticals Inc Stock (ANIP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
0.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):